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ABSTRACT
Challenges and special aspects related to the management and prognosis of pulmonary hypertension (PH) in middle- to
low-income regions (MLIRs) range from late presentation to comorbidities, lack of resources and expertise, cost, and rare
options of lung transplantation. Expert consensus recommendations addressing the speciﬁc challenges for prevention
and therapy of PH in MLIRs with limited resources have been lacking. To date, 6 MLIR-PH registries containing mostly
adult patients with PH exist. Importantly, the global prevalence of PH is much higher in MLIRs compared with highincome regions: group 2 PH (left heart disease), pulmonary arterial hypertension associated with unrepaired congenital
heart disease, human immunodeﬁciency virus, or schistosomiasis are highly prevalent. This consensus statement provides
selective, tailored modiﬁcations to the current PH guidelines to address the speciﬁc challenges faced in MLIRs, resulting
in the ﬁrst pragmatic and cost-effective consensus recommendations for PH care providers, patients, and their families.
(J Am Coll Cardiol 2020;75:2463–77) © 2020 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).

From the aDepartment of Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan; bDepartment of Pediatric
Cardiology and Critical Care, Hannover Medical School, Hannover, Germany; cCongenital and Structural Cardiology, University
Hospitals Leuven, Leuven, Belgium; dDivision of Pediatric Cardiology, Kardiozentrum, La Paz, Bolivia; eDepartment of Cardiology,
Peking Union Medical College Hospital & Key Lab of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences and
Peking Union Medical College, Beijing, China; fDivision of Pediatric Cardiology, Department of Pediatrics, Medical University Graz,
Graz, Austria; gInstituto Nacional de Saúde, Vila de Marracuene, Maputo, Mozambique; hSecondary Hypertension Department
with Pulmonary Hypertension Center, State Institute National Scientiﬁc Center, MD Strazhesko Institute of Cardiology of
Ukrainian National Academy of Medical Science, and Bogomolets National Medical University, Kyiv, Ukraine; iDepartment of
Listen to this manuscript’s
audio summary by
Editor-in-Chief
Dr. Valentin Fuster on
JACC.org.

Pediatric Cardiology, Charité University Medical Center, Berlin, Germany; jHatter Institute for Cardiovascular Research in Africa,
Departments of Medicine and Cardiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; and the
k

Department of Pediatric Cardiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India. This research received no speciﬁc

grant from any funding agency or industry, except for travel grants from the not-for-proﬁt European Pediatric Pulmonary Vascular
Disease Network. Dr. Hansmann was supported by the German Research Foundation (KFO311 HA4348/6-2). Dr. Budts has served
on the Speakers Bureau, received honoraria as a consultant, and has served on the Advisory Board for Abbott (moderate) and
Occlutech (moderate). Dr. Heath own shares of PFM S.R.L. (none of the products are related to this work). Dr. Koestenberger has
served on the Advisory Board for Johnson & Johnson and Actelion (moderate). All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose. Endorsing scientiﬁc societies: AEPC ¼ Association for European
Paediatric and Congenital Cardiology; CSC ¼ Chinese Society of Cardiology; PASCAR ¼ Pan African Society of Cardiology;
PCS ¼ Pakistan Cardiac Society; PCSI ¼ Pediatric Cardiac Society of India.

ISSN 0735-1097

https://doi.org/10.1016/j.jacc.2020.03.047

2464

Hasan et al.

JACC VOL. 75, NO. 19, 2020
MAY 19, 2020:2463–77

Pulmonary Hypertension in Middle- and Low-Income Regions

P

ABBREVIATIONS
AND ACRONYMS
AVT = acute pulmonary

ulmonary hypertension (PH) is a complex condition that associates with
multiple diseases and may affect

several organs beyond the cardiovascular

vasoreactivity testing

CHD = congenital heart disease
COR = class of

and respiratory systems. Challenges intrinsic
to clinical programs in middle- and lowincome regions (MLIRs) affect diagnosis and

recommendation

treatment of PH. These challenges range

echo = echocardiography
EPPVDN = European Pediatric

from lack of resources to cost of care, limited

PVD Network

expertise, unpredictable availability of med-

HFpEF = heart failure with

ications, and the extremely rare option of

preserved ejection fraction

lung transplant (1–4). The disease spectrum

HIR = high-income region

is further complicated by late presentation

LHD = left heart disease

and coexisting comorbidities (i.e., infections,

LOE = level of evidence

malnutrition, and hypercoagulability). Addi-

MLIR = middle- to low-income

tionally, lack of data from MLIRs leads to

region

extrapolation of etiology, diagnosis, and

PVD = pulmonary vascular

management algorithms from high-income

disease

regions (HIRs) that may not address some of

SCD = sickle cell disease

the contextual issues intrinsic to MLIRs (2,3).
The purpose of this expert consensus

WSPH = World Symposium on
Pulmonary Hypertension

statement is to highlight the speciﬁc challenges in the diagnosis and treatment of PH in MLIRs.

HIGHLIGHTS
 PH in MLIRs is under-recognized; PAH
due to CHD/HIV/schistosomiasis and
group 2 PH (left heart disease) are more
prevalent in MLIRs than in HIRs.
 Unmet need for speciﬁc, feasible recommendations for the diagnosis and treatment of PH in MLIRs.
 Here, an expert consensus panel proposes such recommendations for the
global management of PH in MLIRs.
 PH registries and intensiﬁed collaborations between MLIRs are required.
HIRs (10); they are primarily based on expert opinion.
Several etiologies in children and young adults living in
MLIRs are discussed. The importance of such a document
still exists given the challenges associated with such a
disease in a limited resource environment as MLIRs.

METHODS

Following a pragmatic approach with clear cost-riskbeneﬁt consideration, we developed a consensus

GOALS AND COMPOSITION OF THE EPPVDN WRITING

statement with a focus on PH in children and young

GROUP (PH IN MLIRs). The EPPVDN is a registered

adults. This consensus statement does not replace

nonproﬁt organization that strives to deﬁne and

but must be seen as supplementary to previously

develop effective, innovative diagnostic methods and

published recommendations and guidelines by the

treatment options in all forms of PH (Supplemental

European Society of Cardiology (ESC) and European

Methods). Most recently the EPPVDN has revised

Respiratory Society (5), the American Heart Associa-

their 2016 executive summary (11) to develop 2019

tion/American Thoracic Society (6), the publications

updated guidelines on pediatric PH (10) acknowl-

produced by the World Symposium on Pulmonary

edging the changes put forward at WSPH 2018 (7–9).

Hypertension (WSPH) 2018 (7–9) and the European
Pediatric

Pulmonary

Vascular

Disease

Here, we highlight and discuss the challenges and

Network

special aspects in the diagnosis and treatment of PH in

(EPPVDN) (10). We will not discuss all aspects of PH

MLIRs, and for the ﬁrst time, give speciﬁc expert

covered in the aforementioned papers. Health care

recommendations. This expert consensus statement

practitioners from MLIRs are encouraged to read the

is not restricted to pediatric patients and includes

ESC/European Respiratory Society guidelines (5),

disease etiologies and the management of PH in both

along with the update on pediatric PH provided by

children and (younger) adults in MLIRs. We deﬁned

the WSPH and the 2019 updated guidelines of the

MLIR as a region where the majority of people live in

EPPVDN (10), and then use this document to help

countries that have a gross national income (previ-

modify practices contextualized to their own setting.

ously known as gross national product), below 10,000

The current PH registries in MLIRs have minimal

U.S. dollars per capita, as published by The World

information on patients <18 years of age; thus, the

Bank. The executive writing group members for this

suggested recommendations on the care of children

consensus statement on PH in MLIRs were recruited

with PH in this document are an extrapolation from

from Austria, Belgium, Bolivia, China, Germany, India,

both adults with PH in MLIRs and children with PH in

Mozambique, Pakistan, South Africa, and Ukraine.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit
the JACC author instructions page.
Manuscript received February 26, 2020; revised manuscript received March 19, 2020, accepted March 23, 2020.
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LITERATURE

SEARCH,

RECOMMENDATIONS,

Literature
searches

of

GRADING
AND

SYSTEM

REVIEW

OF

PROCESS.

s e a r c h . We conducted computerized
the

PubMed/MEDLINE

bibliographic

T A B L E 1 Classes of Recommendations

COR

Deﬁnition

COR I

Evidence and/or general agreement that a
given treatment or procedure is
beneﬁcial, useful, and effective.

COR II

Conﬂicting evidence and/or a divergence of
opinion about the usefulness/efﬁcacy
of the given treatment or procedure.

COR IIa

Weight of evidence/opinion is in favor of
usefulness/efﬁcacy.

Should be considered

COR IIb

Usefulness/efﬁcacy is less well established
by evidence/opinion.

May be considered

COR III

Evidence or general agreement that the
given treatment or procedure is not
useful/effective and in some cases may
be harmful.

Is not recommended

database from January 1990 to January 2020. Clinical
trials,

consensus

2465
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statements,

guidelines,

meta-

analyses, and comprehensive clinical reviews were
searched using the terms “pulmonary hypertension”
and up to 10 other key words. The writing group
members discussed the topics during several faceto-face and web-based meetings (2018 to 2019).
Class of recommendation, Level of Evidence.
Details on the ESC/American Heart Association

Suggested Wording to Use

Is recommended/is indicated

grading system for Class of Recommendation (Table 1)
and Level of Evidence (Table 2), as well as the voting,
peer review, and endorsement process can be found

Classes of recommendations (COR), as currently proposed by the European Society of Cardiology and the
American Heart Association. This color coding for COR can be found in Table 7.

in the Supplemental Appendix. Importantly, health

PAH is between 15 and 60 per 1 million adults (13).

care providers must adhere to the medication labeling

There is a dearth of data on the incidence, prevalence,

and follow future drug recommendations/warnings,

and causes of PH (pre-capillary, post-capillary, and

published by regulatory agencies, such as the Euro-

combined forms) in MLIRs. Although there are regis-

pean Medicines Agency and the U.S. Food and Drug

tries in some of the MLIRs (Central Illustration), most

Administration, when transferring these recommen-

of them only have data on patients with group 1 PH

dations into clinical practice. Challenges speciﬁc to

(e.g., PAH), include mostly patients >18 years of age,

MLIRs will be discussed in each section of this paper
and consensus recommendations will be presented at
the end of the document.
DEFINITION

OF

PH

AND

and have limited patient numbers (Table 3). Although
the PAPUCO (Pan African Pulmonary Hypertension
Cohort) (Africa) (3), PRO-KERALA (Pulmonary Hy-

PAH

IN

MLIRs. PH

is

pertension Registry of Kerala, India) (India) (2), and

currently deﬁned as a mean pulmonary artery pres-

Ukrainian (14) registries included most groups of PH

sure (mPAP) >20 mm Hg at rest in patients

patients (groups 1 to 5 PH), these data cannot be

>3 months, at sea level, determined by cardiac cath-

considered to be representative for all different cau-

eterization (8,12). Because invasive pressure mea-

ses of PH in other MLIRs. The overall burden of PH in

surements are infrequently used for diagnosis of PH

MLIRs is several times higher than that of HIRs, as

in MLIRs, transthoracic echocardiography (echo) is

demonstrated in the Kerala registry where the esti-

the mainstay of diagnostic screening in such regions.

mated incidence was probably 48 per 1 million people in

The right ventricular (RV) to right atrial (RA) pressure

2015 (2). The following conditions are likely to contribute

gradient was estimated by continuous wave Doppler

substantially to the disease burden of PH in MLIRs:

echo (via tricuspid regurgitation velocity [TRV]), and
an estimated RV-RA systolic gradient >50 mm Hg
(TRV >3.5 m/s) was used as a noninvasive cut-off to
deﬁne PH (2,3). Of note, such a noninvasive deﬁnition
may lead to an underestimation of patients with PH in
these registries. The etiologies of PH are diverse and
differ based on patients’ age and geographic location.
Such information may be important, especially when
deciding on resource allocation and cost of care for

 Rheumatic heart disease, which is still a scourge in
most MLIRs.
 Untreated congenital heart disease (CHD): only a
small fraction (<10%) of infants with shunt lesions
from CHD receive timely intervention in MLIRs
(surgery or percutaneous device closure).
 PH due to left heart disease (LHD) (group 2 PH) as a
result of a high burden of coronary artery disease

diagnosing and managing patients with PH in MLIRs
(3,5). Details on hemodynamic deﬁnitions of PH subtypes can be found in the Supplemental Appendix.

EPIDEMIOLOGY (DISEASE BURDEN) AND
ETIOLOGY OF PH IN MLIRs
Data is sparse to determine the global prevalence and
incidence of PH. The estimated global prevalence of

T A B L E 2 Levels of Evidence

LOE A

Data derived from multiple randomized clinical trials or meta-analyses.

LOE B

Data derived from a single randomized clinical trial or large non-randomized studies.

LOE C

Consensus of opinion of the experts and/or small studies, retrospective studies,
registries.

Levels of evidence (LOE), as currently proposed by the European Society of Cardiology and the American Heart
Association. This color coding for LOE can be found in Table 7.
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C E NT R AL IL L U STR AT IO N 6 Registries on Pulmonary Hypertension in Middle- to Low-Income Regions

Pulmonary Hypertension Registries in Middle- to Low-Income Regions (MLIRs)

Colombian registry
• 159 patients
• Group 1 PH
• NYHA FC: 88%
were class II or III

Ukrainian registry
• 281 patients
• 81.5% Group
1 PH; 18.5%
Group 4 PH
(CTEPH)
• NYHA FC:
75% were
class III/IV
• Survival rate
at 3 years:
81.5%

•
•
•

•
RECOPILAR (Argentina)
• 170 patients
• Group 1 PH
• NYHA FC: 79% were
class III or IV

HINPULSAR (Argentina)
• 124 patients
• Group 1 PH
• NYHA FC: 62% were
class III or IV

PRO-KERALA
(Kerala, India)
2003 patients
59% Group 2 PH ;
21.2% Group 1 PH
Mortality at 12
months after
enrollment in the
registry: 4.1%
Rehospitalization at
1 year: 62%

PAPUCO
(Cameron, Mozambique, Nigeria, South Africa)
•
•
•
•

220 patients (5% children)
Group 1, 2 and 3 PH patients
NYHA FC: 66% were class III or IV
Mortality at 6 months after enrollment in the
registry: 21%

Hasan, B. et al. J Am Coll Cardiol. 2020;75(19):2463–77.

PAPUCO (Pan African Pulmonary Hypertension Cohort) involved 4 African countries; PRO-KERALA (Pulmonary Hypertension Registry of Kerala, India) included 50
centers across the state of Kerala in India; HINPULSAR (Hipertensión Pulmonary Asociaciones en la Argentina) included 31 centers in Argentina; RECOPILAR (Registro
Colaborativo de Hipertensión Pulmonaren Argentina); a Colombian registry included 5 centers; and a prospective Ukrainian registry (adult PAH, CTEPH) from a single
referral center in Kyiv, Ukraine. Overall, the majority of the patients in the 6 registries were >18 years of age. CTEPH ¼ chronic thromboembolic pulmonary
hypertension; NYHA ¼ New York Heart Association functional class; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension.

and unrecognized and untreated systemic arterial
hypertension (15,16).

 Human immunodeﬁciency virus (HIV) infection in
endemic regions (35% of patients in PAPUCO) (3).

 PH due to lung disease: especially interstitial or

 The burden of idiopathic pulmonary arterial hyper-

parenchymal lung disease pertaining to high

tension (IPAH) and other conditions listed in the

prevalence of tuberculosis (23% of patients in

WSPH PH classiﬁcation is also substantial, simply

PAPUCO) in MLIRs (3). Parenchymal lung disease

because of the large populations in MLIR regions.

caused by smoking, exposure to air pollutants, and
smoke generated during indoor cooking/heating
without chimney (32% in PAPUCO) (3).
 Schistosomiasis is endemic in several parts of the

Differences in etiologies between HIRs and MLIRs
are evident from the ﬁnding that IPAH is the largest
subgroup

of

PH

in

the

European

COMPERA

(Comparative, Prospective Registry of Newly Initiated

world especially in South America, the Caribbean,

Therapies for Pulmonary Hypertension) registry (18)

Sub-Saharan Africa, and South Asia. It is estimated

whereas PH-LHD (group 2 PH) was found to be the

that 5 to 20 million people worldwide experience

most common cause in PH registries from MLIRs.

the clinical manifestation of PAH caused by Schis-

Among group 1 PH patients (here PAH), unrepaired

tosoma parasite infection (17).

CHD

accounts

for

the

majority

of

cases

and
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T A B L E 3 Characteristics of Pulmonary Hypertension Registries in Middle- to Low-Income Regions (MLIRs)

Registry/Reference

Region

Demographic Data

Main Findings

PAPUCO Registry

Africa

209 adults (median age 48 yrs; IQR: 35.6) and
11 children (age 1–17 yrs) included, 9 specialist
centers in 4 African countries (Nigeria, Cameron,
South Africa, and Mozambique).

69% had left heart disease (Group 2 PH) and 16% had PAH
(Group 1 PH), 11% PH due to lung disease (Group 3 PH);
66% had NYHA functional class III–IV status, 21% mortality
over 6-month follow-up.

Pro-KERALA Registry

Kerala, Southern
India

2,003 adults (mean age 56  16.1 yrs) enrolled over
1 yr from 50 hospitals; estimated incidence is
48 per million adult population.
Mortality (1 yr): 4.1%.
Rehospitalization (1 yr): 62%.

Majority (59%) had left heart disease (Group 2 PH); w20% were
PAH (Group 1 PH); w5% had IPAH (Group 1 PH); w50% of PAH
patients received oral PAH-targeted therapies.

HINPULSAR*

Argentina

124 adult patients (mean age 45  17 yrs) from
31 centers recruited prospectively over 1 yr.

PAH patients only (Group 1 PH): 52% IPAH and 27% CHD-PAH,
78% females. 62% presented in NYHA functional class III/IV.

RECOPILAR†

Argentina

170 adult patients (mean age 51 yrs) recruited
prospectively over 1 yr. Only PAH patients
(Group 1 PH) enrolled.

PAH patients only (Group 1 PH). 52% IPAH, 27% CHD-PAH;
79% women. 70% presented in NYHA functional class III/IV.

Colombian Registry‡

Bogota, Colombia

159 patients (age >18 yrs) recruited retrospectively
over 6 yrs from 5 centers. Only PAH (Group 1
PH) and CTPEH (Group 4 PH) patients enrolled.

PAH (Group 1 PH) and CTPEH (Group 4 PH) patients only. 33% had
CTEPH, 58% men. 88% presented in NYHA functional class II
and III.

Ukrainian Registry (14)

Kyiv, Ukraine

281 patients (mean age 41.7  14.6 yrs) recruited
prospectively between June 2014 and July 2018
from 1 center. 52 patients with CTEPH
(Group 4 PH) and 229 with PAH (Group 1 PH).

Follow-up period was up to 51 months. The Kaplan-Meier survival
rate for the total cohort was 93.3%, 86.8%, and 81.5% at 1, 2,
and 3 yrs.

Data from: *Perna ER, Coronel ML, Echazarreta D et al. Epidemiological proﬁle of pulmonary arterial hypertension in Argentina: insights from HINPULSAR registry. Eur J Heart Fail 2012:Suppl 1:S55. †Lescano
A, Talavera L, Mazzei J, et al. on behalf of RECOPILAR. The advanced functional class and the variables of poor prognosis in pulmonary hypertension. Eur J Heart Fail 2016;18 (suppl. 1):122. ‡Villaquiran C,
Conde R, Torres A, Duenas R. Description of the clinical, functional and hemodynamic characteristics of patients with CTEPH in ﬁve reference centers in Bogota-Colombia, at 2.640 meters above sea level. Am
J Respir Crit Care Med 2015;191:A4846.
CHD ¼ congenital heart disease; CTEPH ¼ chronic thromboembolic pulmonary hypertension; IPAH ¼ idiopathic pulmonary arterial hypertension; IQR ¼ interquartile range; MLIR ¼ middle- to low-income
region; NYHA ¼ New York Heart Association; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension.

contributes substantially to the overall disease

PH, as many patients in MLIRs do not undergo a

burden of PH in MLIRs. Table 4 summarizes the fea-

diagnostic “gold standard” cardiac catheterization

tures of different PH groups and some of the speciﬁc

(2,3). Using TRV, based on the continuous wave

recommendations relevant to MLIRs.

Doppler envelope, as a measure of RV systolic pressure in PH may still result in underdiagnosing the

CLINICAL PRESENTATION AND
DIAGNOSIS OF PATIENTS WITH PH IN MLIRs

disease. A detailed, multiparameter assessment of the
right heart using a standardized protocol (10,22) will
likely increase the accuracy of echo in detecting PH.

Untreated, undiagnosed PH patients in MLIRs present

Once PH is judged to be highly likely, a diagnostic

late at deﬁnitive diagnosis and with more advanced

approach should be adopted that helps identify cau-

functional

ses with a high likelihood of occurrence and preva-

deterioration

compared

with

HIRs

(Table 3). Similar functional impairment at presentation was observed in the Latin American registries too
(Table 3) (19). Such late presentation with advanced
disease is a major contributor to the very high mortality in PH patients living in MLIRs (Table 3) (2,3).
Indeed, patients with CHD and signiﬁcant left-toright shunts frequently present late in MLIRs and
often have severely increased pulmonary vascular
resistance (PVR). Some of these PAH-CHD patients
may still be operable, despite their older age at presentation, thus warranting comprehensive and careful invasive assessment to determine operability
(20,21).

Our

recommendations

for

the

overall

approach to determine operability of a cardiovascular
shunt lesion in MLIRs is summarized in Supplemental
Table 1.
DIAGNOSTIC WORK-UP. Identifying

lence in a given region/country (Table 4).
Diagnostic

work-up

for

suspected

PH

in

M L I R s . A systematic approach to patients with PH in
MLIRs may help identify causes in a cost-effective
manner (Figure 1, Supplemental Table 2).
Detailed history and physical examination: Helps to
identify a cause and evaluates the clinical status of
the patient. A detailed family history is imperative to
diagnose familial or hereditary PAH.
Chest x-ray: Identiﬁes potential pulmonary etiology or indirect contributors, such as spinal deformity.
Signs of left-sided heart disease may suggest group 2
PH (23).
Transcutaneous pulse oximetry and arterial blood gas
analysis: Can provide information regarding parenchymal/interstitial lung disease (diffusion impair-

PH. Transthoracic

ment) and also operability in CHD shunt lesions (24).

echo is the main diagnostic modality for diagnosis of

Pulse oximetry screening in both the right upper and

2468
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T A B L E 4 The 5 PH Groups and Speciﬁc Considerations in Middle- to Low-Income Regions (MLIRs)

PH Classiﬁcation

Global Prevalence*

Group 1: Pulmonary arterial hypertension Prevalence 15-60 per million
(PAH)
1 PAH
1.1 Idiopathic PAH
1.2 Heritable PAH
1.3 Drug- and toxin-induced PAH
1.4 PAH associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis

Some report prevalence of 0.5
per 1,000 adults with HIVrelated PAH in Africa
(probably overestimated)

Features to be Considered in MLIRs

True incidence and prevalence of HPAH
may be higher in regions with high
rates of consanguinity

Recommendations to be Considered in MLIRs

Genetic testing may not be feasible due to cost or
lack of availability; detailed family history is
imperative

Higher incidence and prevalence of late Screening for unrecognized or latent infections (HIV,
presenting and unrepaired CHD, HIV,
HBV/HCV, schistosomiasis) may be included in
HBV/HCV-induced cirrhosis and portal
the initial workup
hypertension

1.5 PAH long-term responders to calciumchannel blockers
1.6 PAH with overt features of venous/
capillaries (PVOD/PCH) involvement

Underrated due to unrecognized HIV,
history of excessive radiation
exposure, consanguinity

1.7 Persistent PH of the newborn
syndrome

High incidence of prematurity, IUGR
Education of neonatologists to recognize PPHNand intrauterine infections may lead
and CLD-related pulmonary hypertension; proper
to signiﬁcant burden of PPHN or CLD
follow-up of neonates with PPHN

Group 2: PH due to left heart disease
3-4 million people with
2.1 PH due to heart failure with preserved
rheumatic heart disease
LVEF
(RHD)-related PH worldwide
2.2 PH due to heart failure with reduced
LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular
conditions leading to post-capillary PH

High incidence and prevalence of
advanced RHD valvular disease

Group 3: PH due to lung diseases and/or
hypoxia

High incidence and prevalence of
TB-related lung disease

Reduction in RHD burden is an enormous challenge
that needs a concerted global effort. The World
Heart Federation roadmap serves as a foundation
for the development of tailored plans of action to
improve RHD control in speciﬁc contexts.

Group 4: PH due to pulmonary artery
obstructions
4.1 Chronic thromboembolic PH
4.2 Other pulmonary artery obstructions
Group 5: PH with unclear and/or
multifactorial mechanisms
5.1 Hematological disorders
5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease

1-2.5 million people affected by
sickle cell-related PH
worldwide

High incidence and prevalence of sickle
cell disease, thalassemia, chronic
renal failure

Centers are needed with expertise in treating benign
hemoglobinopathies and its related
complications

*Per million adults or individuals affected worldwide. PH classiﬁcation according to the World Symposium on PH 2018, see Simonneau G, et al. (8).
CHD ¼ congenital heart disease; CLD ¼ chronic lung disease; HCV ¼ hepatitis C virus; HBV ¼ hepatitis B virus; MLIR ¼ middle- and low-income regions; IUGR ¼ intrauterine growth restriction;
TB ¼ tuberculosis.

any lower extremity is recommended for evaluating

is important to rule out parenchymal/interstitial lung

post semilunar valve shunt lesions (i.e., patent ductus

disease in suspected PH.

arteriosus or aorto-pulmonary window).
Lung function tests: May help to identify airway

Cardiac catheterization and acute pulmonary vasoreactivity testing (AVT): A number of institutions in

pathologies such as unrecognized asthma or intersti-

MLIRs now have cardiac catheterization laboratory

tial lung disease.

facilities. Although inhaled nitric oxide is largely

Speciﬁc laboratory tests: Work-up to evaluate for

unavailable, preliminary data suggests that inhaled

autoimmune disorders, when clinically appropriate

iloprost (5 m g through a nebulizer over 15 min) and

(23), should be performed. Screening for and diag-

intravenous sildenaﬁl can be used effectively for

nosis of HIV in endemic areas is essential.

AVT at a fraction of the cost compared with inhaled

Abdominal ultrasound: Can help identify diseases

nitric oxide (iNO) (26). Oxygen alone is insufﬁcient

leading to porto-PH or other rare diagnoses such as

and not useful to test for AVT (5). However, oxygen

the Abernethy malformation (25).

alone may be useful when lung disease and diffu-

Computed tomography chest and lung perfusion

sion impairment is suspected to be the major cause of

scans: Might help identify chronic thromboembolic

PH and to determine oxygen-dependence of PAP

pulmonary hypertension (CTEPH). CTEPH is poten-

elevation.

tially treatable and can be identiﬁed through either of

ASSESSMENT OF FUNCTIONAL STATUS AND PH RISK

these tests. Chest computed tomography, if available,

STRATIFICATION. After

PH

diagnosis

is

made
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T A B L E 5 PAH-Speciﬁc Medications and Special Considerations in Middle- to Low-Income Regions (MLIRs)*

Medication Class

Mode of Delivery

Special Considerations in MLIRs

CCBs (e.g., amlodipine)

Oral

 Lack of ability to perform AVT makes it difﬁcult to diagnose acute responders
vs. nonresponders; thus, use of CCB may not be feasible.
 CCBs are contraindicated in PAH-CHD with large shunt and in Eisenmenger
Syndrome.
 CCBs are contraindicated in patients who have not undergone AVT, in proven
non-responders to AVT, and in those with poor cardiac function and/or right
heart failure, regardless of AVT response.
 Ability to follow-up to ensure “responder” status may not be possible.

Phosphodiesterase-5 inhibitors (e.g.,
sildenaﬁl, tadalaﬁl)

Oral i.v. (for special
conditions, i.e., immediate
post-operative)

 Relatively easily available in cheap generic forms (cost w U.S. $2 per 25-mg
oral dose).
 Less side effects; no drug-related adverse event monitoring required.
 Use of medium dose should be encouraged (EMA recommendation 10 mg
3 daily for weight <20 kg and 20 mg 3 daily for weight $20 kg).

Endothelin receptor antagonists (e.g.,
bosentan, ambrisentan, macitentan)

Oral

 Making its way to the MLIR markets; still expensive (especially newer agents).
 Monitoring of liver function may be challenging (bosentan).
 Teratogenicity as risk of unplanned pregnancy may be high in MLIRs.

Prostacyclin analogues and oral prostacyclin
IP receptor agonists

Oral, inhaled, subcutaneous,
and intravenous

 Limited availability in few MLIR countries such as China.
 Frequency of use may signiﬁcantly impair compliance for inhaled medication.
 i.v. infusion option is almost nonexistent in MLIRs because of fundamental
health system challenges.
 Expensive.

Soluble guanylate cyclase stimulators (e.g.,
riociguat)

Oral

 Limited availability in selected MLIRs.
 Expensive.

Supportive medication:

Oral, intravenous

Diuretic agents

 Diuretic agents (furosemide, thiazide) should be used with caution given RV
hemodynamics.

Spironolactone

 Recommended use of spironolactone, a supportive medication in PAH and
proven to be effective in HFpEF.

Digoxin

 Digoxin may be useful particularly in PAH with high heart rates.

Beta-blockers

 Avoid chronic use of beta-blockers in adults with PAH (negative RCT have
been published; no pediatric data available).

Iron and vitamins

 Treat especially iron deﬁciency.
 Oral anticoagulant treatment may be considered in adult patients with IPAH,
HPAH, and PAH due to use of anorexigens (COR: IIb, LOE: C).
 Do not pursue oral anticoagulation without a clear indication and proper
follow-up.
 No data exist to recommend oral anticoagulation in children with PH.
 Of note, many patients with severe PAH do have acquired von Willebrand
syndrome and thus an increased bleeding risk per se.

Oral anticoagulation

*For speciﬁc and detailed dosing recommendations, refer to Hansmann et al. (11).
AVT ¼ acute vasoreactivity testing; CC ¼ cardiac catheterization; CCB ¼ calcium-channel blocker; COR ¼ Class of Recommendation; EMA ¼ European Medical Association; ESC/ERS ¼ European Society of
Cardiology/European Respiratory Society; HFpEF ¼ heart failure with preserved ejection fraction; iNO ¼ inhaled nitric oxide; i.v. ¼ intravenous; LOE ¼ Level of Evidence; RCT ¼ randomized clinical trials;
RV ¼ right ventricle; other abbreviations as in Table 3 and Supplemental Table 4.

(noninvasively or preferably invasively), functional

and cost (2,3,27–29), both managing PH patients

status (exercise capacity) and PH risk stratiﬁcation of

and improving their ultimate outcome in MLIRs are

the patient can be determined using history (World

major challenges (27–29) (Table 6, Supplemental

Health Organization functional class), easily per-

Table 4). It is imperative that practitioners in

formed tests like the 6-min walk test (in patients age

MLIRs modify the management recommendations

>6 years), echo assessment of RV function and

that apply in HIRs to keep the overall essence but

catheter-based

to make it practical according to the constraints in

hemodynamic

data

(10)

(Supplemental Table 3). The EPPVDN developed a

the

new risk score for children with PH (10) that needs to

approach, maintaining patient compliance will be

MLIR

setting.

Without

such

a

pragmatic

be validated in future prospective studies.

difﬁcult and management will be ineffective in the

MANAGEMENT OF PH IN THE CONTEXT OF
FINANCIAL AND INFRASTRUCTURAL

PAH-TARGETED PHARMACOTHERAPY. Targeted phar-

macotherapy is approved for PAH (group 1 PH); some

CONSTRAINTS IN MLIRs

PAH-targeted medications are also approved for use

Due to several factors intrinsic to MLIRs, ranging from

PAH-targeted medications in other groups of PH

access to health care to unavailability of treatment

(e.g., combined pre- and post-capillary PH) should be

end.

in CTEPH (group 4 PH) (Supplemental Table 4). Using
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T A B L E 6 Perspectives for PH Patients in Middle- to Low-Income Regions (MLIRs)

Ukraine, Eastern Europe,
Western Asia/Middle East

China and Southeast Asia

Indian Subcontinent

Africa

Middle and South America

Incidence of PH and
disease entities

The only available
registry is from
Ukraine. The most
common cause
identiﬁed was PAHCHD followed by
IPAH. HIV, and TBassociated PH and
group 3 PH probably
common (no
systematic data
available).

In the Chinese pediatric
High prevalence of RHD and
unrepaired CHD in the South
PAH registry, the
majority of pediatric
Asia region. Indoor and
PAH patients had
outdoor pollution together
PAH-CHD followed by
with high prevalence of TBrelated lung injury may
IPAH/HPAH, similarly
to the adult PAH
contribute to group 3 PH.
population.

The etiology of PH in Africa is
IPAH has been reported
broad and there is no
as the most
systematically collected data
common type of
on epidemiology.
PAH in Latin
Estimates on the prevalence by
America, although
underlying disease are:
this ranking may be
schistosomiasis (170 million),
due to reporting
RHD (6.5 million), SCD (12
bias. More than 1
million), HIV (20 million),
million with
moderate to severe COPD (30
schistosomiasismillion).
related PH in the
Amazonas Region,
high altituderelated PH (acute
and chronic), and
PAH due to
untreated left-toright cardiovascular
shunting with CHD.

Diagnostic options

Echocardiography and
cardiac catherization
available only in
selected centers.

Echocardiography and
cardiac catherization
available in urban
centers.

Very limited access to cardiac
catheterization and
echocardiography usually
restricted to major urban
areas.

Treatment options

Diverse, for example, in PDE5i, ERA, inhaled and Most pharmacological options
Belarus, PAH drugs
subcutaneous PCAs
(PDE5i, ERA, inhaled and
and lung
available.
subcutaneous prostanoids)
transplantation
LuTx or HLTx available in
available, but only affordable
available. In
selected centers.
to some patients.
Kazakhstan, PAH
Transplantation (LuTx, HLTx)
drugs are usually
available in selected centers.
available for free, but
only to selected PAH
patients. No HLTx in
Kazakhstan.

Comments

Preventive strategies aimed at
Despite principal
The member countries of Today, most PAH patients High birth rates, overcrowding,
availability, only a
poverty, and disorganized
reducing smoking, pollution,
the European Union
are treated with PDE5i
health system. Ongoing efforts
elimination of RHD, HIV, and
minority of PAH
monotherapy.
allow for free mobility
patients have
to establish register studies
schistosomiasis might
within the European National administration
eventually contribute to
access to the
Union and, thus,
announced to cover
(Pro-KERALA and Pakistan
reducing the incidence of PH in
appropriate
registry).
specialized health
bosentan, macitentan,
riociguat, and
Africa.
diagnostic
care in Western
technology and
Europe is often
selexipag by the
medication.
accessible to PAH
health care insurance
system from 2020.
patients.

Echocardiography and cardiac
catherization available in
selected centers.

Echocardiography and
cardiac
catherization
available in selected
centers.

Targeted PAH therapy and
Oral sildenaﬁl is the
ﬁrst-line PAH
transplantation (LuTx, HLTx)
pharmacotherapy in
out of reach for the majority of
Middle and South
1 billion Africans.
America.
Availability of other
drugs differs
between countries.
Transplantation (LuTx,
HLTx) available in
few selected
centers.

For details, see Appendix.
COPD ¼ chronic obstructive pulmonary disease; ERA ¼ endothelin receptor antagonist; HLTx ¼ heart-and-lung transplantation; LuTx ¼ lung transplantation; PCA ¼ prostacyclin analog;
PDE5i ¼ phosphodiesterase 5 inhibitor; SCD ¼ sickle cell disease; other abbreviations as in Tables 3 and 4.

decided upon by PH experts only. Vasodilatory

is U.S. $30, whereas dual therapy (tadalaﬁl plus

agents may worsen clinical status and might cause

ambrisentan) is w$100/month (2). Because the ma-

pulmonary edema, especially in group 2 PH with

jority of people in India are uninsured and live at or

heart failure with preserved ejection fraction and left

below $60/month, affording such therapies with

atrial hypertension of other causes (11). The route of

effective treatment compliance is extremely chal-

PAH drug administration, frequency of use, cost, and

lenging (2). Such a scenario holds true for other

availability can be major limiting factors in the

MLIRs, such as Pakistan, Indonesia, Bangladesh,

compliance with treatment, especially in MLIRs (2,3).

Afghanistan, and others. Table 5 describes the clas-

Several of the PAH drugs are manufactured and

ses, different medications, and speciﬁc consider-

available in some MLIRs, for example, India and

ations

China (Supplemental Table 4). Notwithstanding the

Supplemental Table 4). The objective of improving

substantially reduced prices, these medications are

quality of life needs to be discussed up-front with

still very expensive for the average patient in MILRs.

families

In India, the monthly cost of therapy with sildenaﬁl

costly pharmacotherapy.

for

to

PH

in

make

MLIRs

an

(see

informed

also

Table

decision

6,

on
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F I G U R E 1 Algorithm for the Diagnostic Work-Up of Suspected or Conﬁrmed Pulmonary Hypertension in MLIRs Without Access to Cardiac Catheterization

Symptoms, signs and medical
history suggestive of PH
Clinical exam
Clinical exam
supportive of PH

no

yes

Chest X-ray and ECG
Chest X-ray and
ECG supportive of PH

no

Search for other causes
e.g., TB, COPD, PCP,
LHD, Malignancy

yes

ECHO
ECHO supportive of PH

no

yes

Consider common causes

Group 1 PH
IPAH, HPAH, PAH-CHD,
HIV, schistosomiasis
(in Brazil, Caribbean,
Africa), CTD (SLE),
portal hypertension

Group 2 PH
(left heart disease)
Rheumatic heart
disease,
cardiomyopathies

Group 3 PH
(lung disease/hypoxia)
Post TB bronchiectasis
cystic fibrosis,
exposure to domestic
pollution i.e., burning
wood, charcoal in
poorly ventilated
houses

Group 4 PH
4.1 CTEPH
(not
common)
4.2 Other PA
obstructions

Group 5 PH
(unclear and/or
multifactorial)

HIV testing
HCV/HBV testing
Urine screening
Abdominal US, LFTs
Autoimmune work-up

Laboratory
testing,
if available

HRCT Chest

CTPA
V/Q scan

Work-up for
sickle
cell disease
(SCD) and other
hemoglobinopathies
Additional workup

The algorithm applies to children and adults living in middle- to low-income regions (MLIRs) with limited health care resources. See Supplemental Table 2.
COPD ¼ chronic obstructive lung disease; CTEPH ¼ chronic thromboembolic pulmonary hypertension; CTPA ¼ chest tomography pulmonary angiography;
ECG ¼ electrocardiogram; echo ¼ echocardiogram; HIV ¼ human immune deﬁciency virus; HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus; HRCT ¼ high resolution
computed tomography; LFT ¼ liver function test; LHD ¼ left heart disease; PCP ¼ pneumocystis carinii (newer term: pneumocystis jirovecii); PH ¼ pulmonary
hypertension; SLE ¼ systemic lupus erythematosus; TB ¼ tuberculosis; US ¼ ultrasound; V/Q scan ¼ ventilation to perfusion scan.
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T A B L E 7 Recommendations for Diagnosis and Management of Pulmonary Hypertension in Middle- to Low-Income Regions (MLIRs)

Recommendations

COR

LOE

Children/young adults with suspected or conﬁrmed PH must be referred to, comprehensively evaluated, and treated in specialized pediatric
centers. In MLIRs, such pediatric centers often have limited resources, and thus children with PH may be referred to centers caring for
adult patients with PH.

I

C

The initial evaluation of a child/young adult with PH must include a comprehensive medical history (speciﬁcally to identify causes like sickle cell
disease, tuberculosis, or operability in shunt lesions), physical examination (in MLIRs speciﬁc causes like rheumatic heart disease) (2,3,23).

I

B

Patients in endemic areas of schistosomiasis who present with symptoms and physical signs of PH must undergo a detailed echocardiogram.
Patients from such endemic areas with PH and signs of pre-hepatic portal hypertension may be suspected to have schistosomiasis-related
PH (17,56).

I

C

Patients with schistosomiasis infection and PH beneﬁt from PAH- directed therapy (mainly sildenaﬁl) (31).

I

C

Patient with active schistosomiasis need treatment with an antihelmintic drug, such as praziquantel (32).

I

C

Patients with rheumatic heart disease (RHD) and PH documented by echocardiography must undergo treatment as per RHD valve treatment
guidelines.

I

C

The need for PAH-targeted medications in patients with RHD should be carefully evaluated and eventually pursued only at centers
specializing in PH.

I

C

In regions where HIV is highly prevalent, patients with symptoms or signs of PH should undergo a detailed transthoracic echocardiogram to
detect PH (57).

I

C

Patients with HIV infection and PH, documented by echocardiography, beneﬁt from PAH speciﬁc medication (especially bosentan). The role of
HAART on the prevalence and outcome of PH secondary to HIV is still controversial (49,57,58).

I

C

III harm

C

Treatment with PAH-speciﬁc medication (especially sildenaﬁl) in patients with SCD-related PH is highly controversial. Oral sildenaﬁl appears
to increase hospitalization rates for pain in SCD, probably related to vaso-occlusive crisis (36).
Patients living at high altitude and with symptoms and signs of PH may undergo a detailed transthoracic echocardiogram to detect PH.

I

C

The initial patient history needs to include all major socioeconomic determinants of compliance (profession, family structure, and proximity
to treating center). Such information is critical to determine the compliance to treatment and subsequent follow-ups in PH patients (3).

I

C

Patients with high altitude-related PH probably beneﬁt from PAH speciﬁc medications (50).

IIa

B

Children <2 yrs of age living in MLIRs with PH and so-called “simple shunts” (ASD, VSD, or PDA) who have normal saturations, signs of
increased pulmonary blood ﬂow, and exclusive left-to-right shunt on echocardiography may undergo shunt closure without invasive
hemodynamic evaluation (59,60).

IIb

C

In children with cardiovascular shunt lesions, noninvasive oxygen saturations and—if possible—arterial PaO2 during exercise should be measured.
A drop in PaO2 of >10 mm Hg or SpO2 by 19% points during exercise indicates an inoperable shunt due to increased PVR (59–61).

I

C

A comprehensive echocardiogram at diagnosis is recommended as this is the main (and may be the only) modality of diagnosing PH. Features
of operability in shunt lesions should also be assessed using echocardiogram. Serial echocardiograms and ECGs may not be feasible in MLIRs
(due to lack of expertise and equipment) or not be cost-effective, and may be performed on a case-by-case basis (2,3,22).

I

B

Further imaging (mainly chest CT) is recommended to exclude underlying parenchymal/interstitial lung disease, in ex-premature infants, and in
patients with BPD, Down syndrome, or other well-known risk factors (3,23,59).

I

B

Cardiac catheterization for diagnosis or routine follow-up should be performed in PH centers only. Lack of expert centers and standardization
of cardiac catheterization in MLIRs may lead to erroneous data, wrong data interpretation, or little management value. In the absence of
vasoreactivity testing, the value of cardiac catheterization (especially if done for shunt operability) is limited (2,3,62,63).

IIa

B

If no underlying cause of the PH is evident, speciﬁc tests for HIV, schistosomiasis, and chronic hepatitis (HBV and HCV) must be performed.
An abdominal ultrasound is indicated to rule out liver cirrhosis and/or portal hypertension (2,3,64)

I

B

Serial 6MWTs must include pulse oximetry and are recommended to assess exercise tolerance and response to therapy, and to estimate
prognosis in children with PH capable of performing such studies. A 6MWT is an inexpensive, reproducible measure of functional capacity.
Equipment and expertise for CPET are rarely available in MLIRs (65).

I

C

PAH-speciﬁc therapy is recommended and can signiﬁcantly improve quality of life. Safety of intravenous therapy in a low-resource setting is
also of concern (higher risk of infection and catheter-based complications). Inhalation therapies are often ineffective due to lack of sufﬁcient
patient compliance and/or difﬁculties with applying the devices at home (2,3,66).

I

B

For children with PH/PHVD undergoing surgery or other interventions requiring sedation or general anesthesia, consultation with cardiac
anesthesia and PH service and appropriate post-procedure monitoring are required (67,68).

I

C

IIb

C

IIb

C

Atrial septostomy and other surgical measures (e.g., reverse Potts shunt) and interventional procedures (ductal stenting, balloon atrial
septostomy) may be considered in highly selected cases at very few specialized centers. These procedures are risky per se and especially in
MLIRs, with inconclusive long-term beneﬁts especially in the absence of a lung transplant program (54,55,69).
Serial measurements of serum NT-proBNP concentration may be indicated as changes in NT-proBNP reﬂect hemodynamic impairment.
Cost-beneﬁt assessment of this test is needed in MLIRs health care setting (5).*

Recommendations speciﬁc to MLIRs are predominantly based on expert opinion due to lack of publications from these regions. *Based on RCT study data not speciﬁc to MLIR, serial measurements of serum
NT-proBNP concentration should be considered (COR IIa) as changes in NT-proBNP reﬂect hemodynamic impairment. These recommendations are taken with permission (slightly modiﬁed) from Table 12 in
Hansmann et al. (10).
6MWT ¼ 6-min walk test; ASD ¼ atrial septal defect; CPET ¼ cardiopulmonary exercise testing; HAART ¼ high activity anti-retroviral therapy; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide;
PaO2 ¼ arterial partial pressure of oxygen; PDA ¼ patent ductus arteriosus; PPHVD ¼ pediatric pulmonary hypertensive vascular disease; PVR ¼ pulmonary vascular resistance; PVD ¼ pulmonary vascular
disease; RV ¼ right ventricle; SCD ¼ sickle cell disease; SpO2 ¼ oxygen saturation; VSD ¼ ventricular septal defect; other abbreviations as in Tables 3 and 4.
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PREGNANCY AND CONTRACEPTION. Pregnancy in

patients may develop parenchymal lung disease from

female PH patients is associated with substantial risk

recurrent acute chest syndrome, while others develop

of maternal and fetal mortality; thus, relevant coun-

CTEPH. Despite PAP being only moderately elevated in

seling is very important, especially in MLIRs (30).

most SCD patients, PH has a negative inﬂuence on ex-

Safer

progesterone

ercise capacity (33) and markedly increases the risk of

impregnated intrauterine coils, subdermal or intra-

death in SCD patients compared with those without

muscular progesterone implants/injections) may not

PH. Treatment with PAH-targeted medication (espe-

be readily available in MLIRs. Standard oral estrogen-

cially sildenaﬁl) in patients with SCD-related PH is

based contraceptive is associated with increased risk

controversial and may lead to an increase in SCD-

of thrombosis (30). In the event of pregnancy, if the

related vaso-occlusive crisis (36). For most patients

contraception

options

(i.e.,

mother wants to continue, close follow-up with high-

with SCD who have PH (conﬁrmed by cardiac cathe-

risk obstetric care is recommended, especially at the

terization), we do not recommend administration of

time of delivery and within the 2 weeks postpartum,

any PAH-targeted therapy (Table 7) (37). Furthermore,

when the risk of death is the highest, often due to

hydroxyurea is the ﬁrst-line therapy in patients with

thromboembolic complications or heart failure (30).

SCD who are at increased risk for mortality, according
to American Thoracic Society criteria from 2014

SPECIAL THERAPEUTIC CONSIDERATIONS

(TRV $2.5 m/s, serum N-terminal pro-brain natriuretic

IN MLIRs

peptide $160 pg/ml, or presence of PH by cardiac

PH ASSOCIATED WITH SCHISTOSOMIASIS. Schisto-

somiasis is the most common parasitic disease associated

with

PH

(17).

The

cause

of

PH

in

schistosomiasis is multifactorial, including parasitic
pulmonary artery embolization, pulmonary vasculopathy, and portal hypertension related to hep-

catheterization, as deﬁned at the time by mean pulmonary artery pressure $25 mm Hg) (37). Recently,
promising results have been reported using chronic
blood exchange transfusions in SCD with pre-capillary
PH (38).
PH ASSOCIATED WITH THALASSEMIA. The preva-

atosplenic disease (17) that can be diagnosed by

lence of PH in patients with b-thalassemia intermedia

abdominal ultrasound. A high index of suspicion of

(TI) is quite high, and exceeds those with b -thalas-

schistosomiasis-induced PH should be present when

semia major (TM) (4.2% vs. 1.1%) (39). In contrast, PH

patients present with cardiovascular symptoms and

is rarely found in patients with a -thalassemia (Bart or

features of PH in schistosomiasis endemic areas

Hemoglobin H disease) (39). Of note, PH in thalas-

(Supplemental Figure 1) (17). The cornerstone of cur-

semia is multifactorial in nature, that is, chronic he-

rent schistosomiasis control programs is delivery of

molysis leading to impaired NO bioavailability,

praziquantel to at-risk populations. World Health

restrictive cardiomyopathy due to myocardial side-

Organization guidelines recommend annual treat-

rosis, liver siderosis-related cirrhosis or viral hepati-

ment for schistosomiasis or soil-transmitted helmin-

tis, pulmonary siderosis, transfusion-related HIV

thiasis when prevalence in school-aged children is at

infection, change in circulating erythrocytes post

or above a threshold of 50% and 20%, respectively.

splenectomy (40), and hypercoagulability leading to

No speciﬁc test exists to diagnose schistosomiasis-

higher risk (1% to 4%) of thromboembolic episodes

induced PH. Patients with schistosomiasis infection

(41). Thus, suspected PH associated with any type of

and PH may beneﬁt from PAH-directed therapy

thalassemia requires a careful and systemic approach

(mainly sildenaﬁl) (31). Patients with active schisto-

to conﬁrm the diagnosis. A high index of suspicion is

somiasis need immediate treatment with an anthel-

required, because symptoms of PH in thalassemia

mintic drug, such as praziquantel (32).

patients may mimic those related to anemia. Chronic
transfusion protocol with appropriate iron chelation

PH ASSOCIATED WITH SICKLE CELL DISEASE. In a

strategies may prevent and also improve PH in these

systematic review of PH in Africa, the prevalence of PH

patients (42). Hydroxyurea therapy in b-TI and L-

in sickle cell disease (SCD) was 36.9% (29.7% to 44.3%)

carnitine in TM patients have been shown to improve

(27) with a mean age of 28.6  5.8 years at presentation

PH (43). There is limited data on use of PAH-speciﬁc

(33). The etiology of PH in SCD is multifactorial, so that

medication in thalassemia patients. Sildenaﬁl ther-

all 5 groups of PH (mainly groups 1 to 3) occur (8,27). PH

apy in b-TM patients (44), tadalaﬁl in b-TI patients

in SCD is often linked to left heart failure (27,34,35) due

(45), and bosentan in b-TI patients have been used.

to chronically elevated cardiac output, LV diastolic

Due

dysfunction, or coronary ischemia. Furthermore, SCD

cautiously used with close monitoring (11). Limited

to

its

liver

toxicity,

bosentan

should

be

2473

2474

Hasan et al.

JACC VOL. 75, NO. 19, 2020
MAY 19, 2020:2463–77

Pulmonary Hypertension in Middle- and Low-Income Regions

data exist on the use of prostacyclin analogs in

and reverse (right–left) ﬂow across the shunt. Goal

these patients.

of treatment is improving quality of life and dealing

PH ASSOCIATED WITH HIV INFECTION. HIV-infected

patients have a greater incidence of PH compared with
the general population (46) and a 2,500-fold increased
risk of developing PAH. A systematic review and metaanalysis of cardiac dysfunction in HIV reported a
prevalence of PH of 11.5% in 125,382 HIV-infected
adults (5.5% to 19.2%) (47). However, in a prospective
cohort registry of 220 African PH patients, HIV/acute
immune deﬁciency syndrome was found in <10% of PH
cases (3). HIV-related PAH reduces the probability of

with complications (Supplemental Table 5) that arise
in Eisenmenger syndrome (53). In patients with
Eisenmenger syndrome and neurological symptoms
(minor stroke), phlebotomy may be considered in
severe hyperviscosity (hematocrit $70%); however,
iron deﬁciency from frequent phlebotomies must be
avoided. Routine phlebotomy is associated with
increased risk of stroke and also leads to relative
anemia and reduction in exercise tolerance.
ATRIAL SEPTOSTOMY OR REVERSE POTTS SHUNT

survival by one-half compared with HIV-positive in-

AS PALLIATIVE OR BRIDGING THERAPIES. Atrial

dividuals without PAH (48). Patients with HIV infec-

septostomy or reverse Potts shunt as palliative or

tion and PH suspected by echo may beneﬁt from PAH-

bridging therapies are typically used to improve qual-

targeted therapy (especially bosentan) (49). The role of

ity of life, as a bridge to lung transplantation (54,55), or

high-activity antiretroviral therapy on the prevalence

as destination therapy (54). Both procedures carry

and outcome of PH associated with HIV is still contro-

signiﬁcant risk and require a high level of expertise.

versial (49).

Very few advanced centers in MLIRs attempt such

PH ASSOCIATED WITH HIGH ALTITUDE. PH in the

interventional therapies (mainly reverse Potts shunt:

presence of chronic hypobaric hypoxia is per deﬁnition endemic. In La Paz, Bolivia, at 3,350 m above sea
level (a cohort of 4,469 patients), 206 of 1,217 (17%)
infants <3 months had signs of PH. Based on the La
Paz experience, it is recommended to treat these
newborns and young infants with echo evidence of
PH with PDE5 inhibitors (oral sildenaﬁl 1 mg/kg
bodyweight every 6 h). Older patients, who develop
PH speciﬁcally related to high altitude, primarily
need to be referred to lower regions, where pulmonary pressure usually drops to normal levels. No
medication is needed in this clinical scenario in most
instances. Prophylactic use of pulmonary vasodilators to prevent high altitude–induced PH is discouraged as in some studies it has been shown to cause
harm (50).
CHD at high altitude occurs with a rather different
anatomical distribution (e.g., patent ductus arteriosus [PDA], atrial septal defect, tricuspid atresia, and
Ebstein anomaly are more common than at sea level).
Children living at high altitude have a 10-fold chance
of having a hemodynamically relevant PDA (51). The
presentation and clinical evolution of CHD lesions
also differs at high altitude compared with similar
patients residing at sea level (52). For example, left to
right shunt lesions (PDA, ventricular septal defect)
have a delayed progression toward an inoperable
state and should be assessed for operability even after
childhood.
HYPOXEMIA

surgery or catheter intervention) and consider them
only in selected cases. Developing skills in performing
these procedures may be beneﬁcial, especially in
countries where intravenous PAH therapy or lung
transplantation are not available. Continuous combination PAH-pharmacotherapy is required after atrial
septostomy or reverse Potts shunt for the underlying
advanced pulmonary vascular disease/PAH.

EXPERT RECOMMENDATIONS ON THE
DIAGNOSIS AND TREATMENT OF PH IN MLIRs
The majority of our recommendations (Table 7) are
extrapolated from previously published European or
North American guidelines and consensus statements
(5,6,11). Modiﬁcation pertaining to MLIRs has minimum data support and are predominantly expert
opinions (Level of Evidence: C). The focus is on
diagnosis and management of PH, keeping in mind a
high prevalence and a broad etiology of the disease.
Special attention is given to the diagnosis of LHD (i.e.,
rheumatic heart disease), acquired lung diseases (i.e.,
tuberculosis), infections such as HIV and schistosomiasis, and unrepaired CHD. The most signiﬁcant
challenge in PH management includes unavailability
of PAH-targeted medication.

PERSPECTIVES FOR PH PATIENTS IN MLIRs
The perspectives for PH patients and their health care

AND

EISENMENGER

SYNDROME. Eisen-

speciﬁc to certain region and countries in MLIRs are

menger syndrome is present in unrepaired shunt

summarized in Table 6, and further discussed in

lesions and is characterized by cyanosis, clubbing,

more detail in the Supplemental Appendix.
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SUMMARY AND GLOBAL PERSPECTIVES

pragmatic

approach

with

clear

cost-risk-beneﬁt

evaluation along with an honest discussion among
PH is a progressive and often fatal condition that is

health care providers, patients, and their families.

more common in MLIRs than in HIRs; PH is

Registry and other collaborative study data for na-

underdiagnosed in MLIRs where it is handled by

tional advocacy and government supported health

cardiologists who often serve both children and

care plans will be crucial for the managing of young

adults with limited access to advanced health care.

PH

Importantly, on a global scale, PH is not a rare

resources.

patients

in

MLIRs

with

limited

economic

disease but is a major health care burden worldwide, for example, when associated with rheumatic
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